{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:42:14Z","timestamp":1777934534431,"version":"3.51.4"},"reference-count":20,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T00:00:00Z","timestamp":1642636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The study aimed to assess the effectiveness of Imatinib in chronic myeloid leukaemia (CML) in our hospital population. In addition to identify which brand of imatinib (Gleevec\/Veenat) is cost effective for CML patients and to assess the possible adverse drug reactions during the treatment for chronic myeloid leukaemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A non-interventional (observational), both retrospective and prospective study was carried out in the department of Medical Oncology and Haematology of our hospital. A total of 152 patients were enrolled in the study. Patients who satisfied the inclusion and exclusion criteria were selected for the study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Evaluation of baseline characteristics of study population (n\u2009=\u2009152) showed predominance of males (65.1%). The mean age was 49.80\u2009\u00b1\u200916.561 years. The overall clinical outcome of the sample population, BCR ABL value responses during 3,6 and 12 months are the main indicators for the prediction of outcome in CML -CP patients. Using Independent sample t test, it was found that the difference in response to Imatinib therapy during 3,6 &amp; 12 months were statistically significant and showed a statistically significant difference between the good and adverse outcome (p\u2009&lt;\u20090.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study concluded that Imatinib showed a benefit in treating the condition without any life-threatening adverse events and also the drug exhibits a complete haematological and optimal response based on European Leukaemia Net criteria during the period of study. From which, it can be concluded that imatinib appears to be a safe and well-tolerated treatment for the chronic-phase chronic myeloid leukaemia population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552221074272","type":"journal-article","created":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T07:28:16Z","timestamp":1642663696000},"page":"547-556","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Assessment of Imatinib as a Primary Treatment of Chronic Myeloid Leukemia in Chronic Phase: a Cohort Study"],"prefix":"10.1177","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0646-1532","authenticated-orcid":false,"given":"Dana","family":"Merin","sequence":"first","affiliation":[{"name":"Pharm D, Intern, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Sciences Campus, Kochi-682041, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akshaya","family":"Krishna","sequence":"additional","affiliation":[{"name":"Pharm D, Intern, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Sciences Campus, Kochi-682041, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1053-4394","authenticated-orcid":false,"given":"Sreelekshmi","family":"Jayakumar","sequence":"additional","affiliation":[{"name":"Pharm D, Intern, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Sciences Campus, Kochi-682041, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Mahima","sequence":"additional","affiliation":[{"name":"Pharm D, Intern, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Sciences Campus, Kochi-682041, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K N","family":"Anila","sequence":"additional","affiliation":[{"name":"Assistant Professor, Department of Pharmacy Practice, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Sciences Campus, Kochi-682041, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neeraj","family":"Sidharthan","sequence":"additional","affiliation":[{"name":"Amrita Institute of Medical sciences and Research Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,1,20]]},"reference":[{"key":"e_1_3_3_2_2","first-page":"65","article-title":"A review of chronic myeloid leukemia and its pharmacotherapy","volume":"4","author":"Khan N","year":"2014","unstructured":"Khan N, Abbas A. A review of chronic myeloid leukemia and its pharmacotherapy. International Journal of Pharmacotherapy 2014; 4: 65\u201367.","journal-title":"International Journal of Pharmacotherapy"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S191303"},{"key":"e_1_3_3_4_2","article-title":"A review on newer tyrosine kinase inhibitors and their uses","author":"Kumar NM","unstructured":"Kumar NM, Mathew M, Anila KN, et al. A review on newer tyrosine kinase inhibitors and their uses. Journal of Clinical & Diagnostic Research 2018; 12: 1\u20133.","journal-title":"Journal of Clinical & Diagnostic Research"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401565"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/357027"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609324"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.2147\/BTT.S5775"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1177\/2399369320946760"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.366"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-131-3-199908030-00008"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30864"},{"key":"e_1_3_3_13_2","first-page":"3947","article-title":"A high serum uric acid level is associated with poor prognosis in patients with acute myeloid leukemia","volume":"33","author":"Yamauchi T","unstructured":"Yamauchi T, Negoro E, Lee S, et al. A high serum uric acid level is associated with poor prognosis in patients with acute myeloid leukemia. Anticancer Res 2013 Sep 1; 33: 3947\u20133951.","journal-title":"Anticancer Res"},{"key":"e_1_3_3_14_2","first-page":"872","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani M","unstructured":"Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood, The Journal of the American Society of Hematology 2013 Aug 8; 122: 872\u2013884.","journal-title":"Blood, The Journal of the American Society of Hematology"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.0779"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-02-005686"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0776-2"},{"key":"e_1_3_3_18_2","first-page":"101","article-title":"Imatinib in the treatment of chronic myeloid leukemia: current perspectives on optimal dose","volume":"5","author":"Waclaw J","year":"2015","unstructured":"Waclaw J, Sacha T, Stoklosa T. Imatinib in the treatment of chronic myeloid leukemia: current perspectives on optimal dose. Blood Lymphat Cancer 2015; 5: 101.","journal-title":"Blood Lymphat Cancer"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24066"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1177\/2040620712468289"},{"key":"e_1_3_3_21_2","first-page":"iii","article-title":"Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukaemia in chronic phase: a systematic review and economic analysis","volume":"8","author":"Dalziel K","unstructured":"Dalziel K, Round A, Stein K, et al. Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukaemia in chronic phase: a systematic review and economic analysis. Health technology assessment (Winchester, England) 2004 Jan 1; 8: iii\u2013ii1.","journal-title":"Health technology assessment (Winchester, England)"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552221074272","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552221074272","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552221074272","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:26:21Z","timestamp":1777688781000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552221074272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,20]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["10.1177\/10781552221074272"],"URL":"https:\/\/doi.org\/10.1177\/10781552221074272","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,20]]}}}